A Study of QLM2011 in Subjects With Advanced Solid Tumors
NCT06925659
Phase
Phase 1
Recruitment status
Not yet recruiting
Participants
Lead sponsor
Qilu Pharmaceutical (Hainan) Co., Ltd.
Start date
2025-05-01
- Summary
- This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The purposeaim of this study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of QLM2011 in patients with advanced solid tumors.
- Short title
- A Study of QLM2011 in Subjects With Advanced Solid Tumors
- Official title
- A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of QLM2011 in Patients With Advanced Solid Tumors
- Control arm
- Open label
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Not yet recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Completion date
- 2027-02-01
- First posted
- 2025-04-13
- Registry last updated
- 2025-04-17
- Primary completion date
- 2026-06-01
- Start date
- 2025-05-01
- Participants
- Participant count basis
- Estimated
- Planned participants
- Protocol amendments
- Registry sponsor category
- Industry
- Lead sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT06925659
- ClinicalTrials.gov ID
- NCT06925659
- Registry record
- Open registry record
- Allocation
- Not randomised
- Model
- Sequential
- Purpose
- Treatment
- Masking
- No masking
Sources for study design
Dose-limiting toxicity (DLT)
Timeframe: 21 days
The DLT of QLM2011 will be determined.
Maximum tolerated dose (MTD)
Timeframe: up to 1 years
The maximum tolerated dose (MTD) (if available) of QLM2011.
recommended Phase 2 dose (RP2D)
Timeframe: up to 1 years
recommended Phase 2 dose (RP2D) of QLM2011.
Sources for outcomes
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Healthy volunteers
- No
- Age ≥18, ≤80 years, no gender limitation；
- Histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors, for which standard therapy either does not exist or has proven to be ineffective, intolerable for the patient；
- At least one measurable lesion as per RECIST version 1.1；
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1；
- Life expectancy ≥3 months；
- All subjects of reproductive potential must agree to use an effective method of contraception during the study and for 3 months after the last dose, and women of reproductive age must have a negative blood pregnancy result within 7 days prior to the first dose.
- Chemotherapy, radiotherapy, targeted therapy， endocrine therapy, immunotherapy and other anti-tumor treatment within 28 days of the first dose of the study drug, 6 weeks for nitrosoureas or mitomycin C, 2 weeks (or 5 half-lives whichever is longer) for using fluorouracil or small molecule targeted drugs, 2 weeks for using traditional Chinese medicine with anti-tumor indications.
- Uncontrolled or clinically symptomatic serous cavity effusions (e.g., pericardial effusion, pleural effusion, ascites, etc.) requiring repeated puncture drainage or medical intervention.
- Toxicity from prior antitumor therapy has not recovered to ≤ Grade 1 per the Common Terminology Criteria for Adverse Events (CTCAE v5.0) (exceptions include alopecia, peripheral neuropathy, isolated laboratory abnormalities, or other toxicities deemed by the investigator to pose no safety risk).
- Have a history of other malignant tumors within 3 years before signing the informed consent, excluding cervical carcinoma in situ, basal cell carcinoma of the skin, papillary thyroid carcinoma or squamous cell carcinoma of the skin that has received radical treatment;
Sources for eligibility